Radiolanthanum: Promising theranostic radionuclides for PET, alpha, and Auger-Meitner therapy

Bryce J B Nelson; Jan D Andersson; Frank Wuest

doi:10.1016/j.nucmedbio.2022.04.005

Radiolanthanum: Promising theranostic radionuclides for PET, alpha, and Auger-Meitner therapy

Nucl Med Biol. 2022 Jul-Aug:110-111:59-66. doi: 10.1016/j.nucmedbio.2022.04.005. Epub 2022 Apr 16.

Authors

Bryce J B Nelson¹, Jan D Andersson², Frank Wuest³

Affiliations

¹ Department of Oncology, Cross Cancer Institute, University of Alberta, 11560 University Ave, Edmonton, AB T6G 1Z2, Canada; Cancer Research Institute of Northern Alberta (CRINA), University of Alberta, Edmonton, AB T6G 2S2, Canada.
² Department of Oncology, Cross Cancer Institute, University of Alberta, 11560 University Ave, Edmonton, AB T6G 1Z2, Canada; Cancer Research Institute of Northern Alberta (CRINA), University of Alberta, Edmonton, AB T6G 2S2, Canada; Edmonton Radiopharmaceutical Center, Cross Cancer Institute, Alberta Health Services, 11560 University Ave, Edmonton, AB T6G 1Z2, Canada.
³ Department of Oncology, Cross Cancer Institute, University of Alberta, 11560 University Ave, Edmonton, AB T6G 1Z2, Canada; Cancer Research Institute of Northern Alberta (CRINA), University of Alberta, Edmonton, AB T6G 2S2, Canada. Electronic address: wuest@ualberta.ca.

PMID: 35487834
DOI: 10.1016/j.nucmedbio.2022.04.005

Abstract

Lanthanum radiometals are well positioned to serve as theranostic PET radiometals for targeted radionuclide therapy. The positron emitters ¹³²La and ¹³³La show promise to serve as unique PET imaging agents for ²²⁵Ac targeted alpha-particle therapy, the ¹³⁴Ce/¹³⁴La pair has PET imaging potential with both ²²⁵Ac and ²²⁷Th, and ¹³⁵La has potential in targeted Auger-Meitner electron therapy. With easily accessible cyclotron production routes, effective and efficient chemical separations, and robust chelation chemistry, these radionuclides are well poised for additional preclinical and clinical PET and targeted radionuclide therapy studies. This review summarizes recent advances in radiolanthanum production and preclinical applications that demonstrate the strong potential of these radionuclides in PET and targeted radionuclide therapy.

Keywords: Auger-Meitner therapy; Cyclotron; PET; Radiolanthanum; Theranostics.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Alpha Particles / therapeutic use
Cyclotrons
Positron-Emission Tomography
Precision Medicine*
Radioisotopes* / therapeutic use

Substances

Radioisotopes